Yuan Dong Bio: HP-002 tablets complete the administration of the first subject enrolled in the Phase I/II clinical trial.

Yuan Dong Biological announced that its holding subsidiary, Shanghai Chaoyang Pharmaceutical, has independently developed the Class 1 innovative chemical drug HP-002 tablets, which are used for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. The phase I/II clinical trial recently completed the enrollment of its first subject. This drug received clinical trial approval from the National Medical Products Administration on May 29, 2026, and the initiated phase I dose-escalation stage has completed its first enrollment.